The National Institutes of Health (NIH) is soliciting applications for the Limited Competition: Regenerative Medicine Innovation Project (RMIP) under the UH3 Exploratory/Developmental Cooperative Agreement Phase II. This funding opportunity seeks renewal applications from investigator-initiated clinical trials that aim to advance regenerative medicine using adult stem cells, as established by the 21st Century Cures Act. Eligible organizations include various educational institutions, non-profits, and for-profit entities. Notably, applicants are required to match federal funding on a 1:1 basis with non-federal contributions. Key project goals include enhancing research on regenerative therapies and overcoming existing barriers in clinical development. The NIH emphasizes the significance of projects that provide valuable data following previous RMIP trials. The expected funding totals up to $3.5 million, with a maximum of $400,000 in direct costs per year per awarded project, and the application period runs through October 22, 2025. NIH grants policies apply, including strict adherence to application guidelines and requirements for sharing data generated from the projects. Applications will be evaluated based on scientific merit, approach, and investigator qualifications, ensuring a focused enhancement of regenerative medicine's impact on health.